Elucidata

Elucidata is a technology company.

Active

Updated: Dec 11, 2025 ·

Recent News & Mentions

Sep 1, 2022FundingElucidata - Series A Jan 1, 2021FundingElucidata - Seed Jun 1, 2018FundingElucidata - Seed

Financial History

Elucidata has raised $23.0M across 3 funding rounds. Most recently, it raised $16.0M Series A in September 2022.

Total Raised

$23.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Other Investors
Sep 1, 2022	$16.0M Series A	645 Ventures, Contrary Capital, Convective Capital, F-Prime Capital Partners, Hyperplane Venture Capital, Pareto Holdings
Jan 1, 2021	$5.0M Seed	645 Ventures, Contrary Capital, Convective Capital, Hyperplane Venture Capital, Pareto Holdings
Jun 1, 2018	$2.0M Seed	645 Ventures, Contrary Capital, Convective Capital, Hyperplane Venture Capital, Pareto Holdings

Financial History

Elucidata has raised $23.0M across 3 funding rounds.

Total Raised

$23.0M

Valuation

N/A

Deep Dive

High-Level Overview

Elucidata is a TechBio company that builds Polly, an AI-powered cloud platform for cleaning, harmonizing, and linking multimodal biomedical data at scale, making it ML-ready for life sciences R&D.[1][2][3] It serves biopharma companies, research labs, and diagnostics firms—such as Pfizer, Janssen, Lilly, Bristol Myers Squibb, and Stanford—solving the core problem of data wrangling, where teams spend 80% of time preparing unstructured omics, clinical, EHR, imaging, and assay data instead of analyzing it.[5][6] Polly supports 26+ data types from 30+ public and proprietary sources, integrates with tools like Spotfire and SageMaker, and delivers 70TB+ of high-quality, SOC2/HIPAA/GDPR-compliant data, accelerating drug discovery, biomarker identification, patient stratification, and precision medicine while cutting costs (e.g., 4X pipeline savings, $1.34M compute reduction).[2][3][5] Recognized as Fast Company's Most Innovative Biotech Company in 2024, Elucidata shows strong growth via a Series A in 2022 led by F-Prime and Eight Roads, with 3 of the top 10 pharmas as customers and processing 35TB/month.[1][3][5]

Origin Story

Elucidata was founded in 2015 by Dr. Abhishek Jha (University of Chicago and MIT graduate) and Swetabh Pathak (IIT Delhi alumnus).[3] The idea emerged from Jha's frustration during biomedical research: uploading and cleaning even one dataset required massive manual effort, and scaling to multiple datasets seemed impossible without platoons of data scientists.[1] Leveraging emerging ML and NLP in the mid-2010s, they built Polly as a code-first platform to automate data wrangling, starting with R&D tabular and text data.[1] Early traction came from biopharma needs in omics analysis; by 2022, a Series A from F-Prime and Eight Roads fueled expansion into pharmacology, clinical trials, and manufacturing data, with Polly now powering 3 of the top 10 pharmas.[1][3]

Core Differentiators

Data Harmonization at Scale: Polly's LLM-powered engine cleans, links, and transforms 26+ data types (omics, EHR, imaging, clinical trials) into a unified ML-ready model with 99.99% accuracy via human-in-the-loop QA/QC, processing 35TB/month—10X faster than manual methods.[2][5][6][7]
Code-First Developer Experience: GUI-optional, integrates seamlessly with Spotfire, SageMaker; supports 30+ bioinformatics pipelines, AI-assisted cohort builders, predictive modeling, and no-code LLM chatbots for 5X faster insights.[1][2][6]
Customizable Quality and Compliance: Granular annotations, metadata extraction, and full transparency with QA reports; SOC2/HIPAA/GDPR compliant, tailored for early R&D, precision diagnostics, and translational research.[2][5][7]
Proven Impact: Trusted by Pfizer, Exelixis, Lilly, BMS; case studies show 2X chatbot performance, 4X cost cuts in AAV sequencing, $1.34M compute savings in RNA-seq, and boosted predictive efficiency in target discovery.[2][5][6]

Role in the Broader Tech Landscape

Elucidata rides the AI-in-biotech wave, advocating a data-centric AI approach where clean, harmonized data trumps raw volume amid trillions of TBs of unusable life sciences data.[1][5] Timing is ideal as biopharma shifts to multimodal data (omics + real-world evidence) for drug discovery, with AI/ML-Ops addressing silos and 80% data prep bottlenecks in a market hungry for faster therapies.[4][6][7] Market forces like rising R&D costs, regulatory demands for secure data, and AI adoption by startups to conglomerates favor Polly's scalable, compliant platform, influencing the ecosystem by enabling 35+ biopharmas/research labs to fast-track from experiment to insight, reducing time-to-discovery.[2][3][5]

Quick Take & Future Outlook

Elucidata is poised to expand beyond R&D omics into pharmacology, clinical trials, manufacturing, and underserved tabular/text data, leveraging Series A momentum and 100+ experts in NLP/bioinformatics for broader AI-ready data products.[1][7] Trends like LLM advancements, multimodal integration, and precision medicine will amplify growth, potentially capturing more of the $100B+ biopharma data market as top pharmas scale usage. Its influence may evolve from data wrangler to end-to-end R&D enabler, flipping the 80-20 data-analysis ratio industry-wide and powering global health breakthroughs—solidifying its TechBio leadership.

Sources

Frequently Asked Questions

How much funding has Elucidata raised?

Elucidata has raised $23.0M in total across 3 funding rounds.

Who are Elucidata's investors?

Elucidata's investors include 645 Ventures, Contrary Capital, Convective Capital, F-Prime Capital Partners, Hyperplane Venture Capital, Pareto Holdings.